Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × INDUSTRY × tucatinib × Clear all

Phase

Status

Completed 9 Active not recruiting 8 Recruiting 5 Terminated 1 Not yet recruiting 1 No longer available 1 Approved for marketing 1

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

HER2-positive Breast Cancer 1

Interventions

Injections 34 Carboplatin 27 Docetaxel 23 Oxaliplatin 22 Capecitabine 21 pembrolizumab 20 Paclitaxel 20 Cisplatin 19 Gemcitabine 16 Bevacizumab 16 Pemetrexed 14 Cyclophosphamide 12 Fluorouracil 11 tislelizumab 9 Leucovorin 9 Irinotecan 9 Drug Therapy 9 osimertinib 8 Doxorubicin 7 fludarabine 6 Trastuzumab 6 Nivolumab 6 palbociclib 5 lenvatinib 5 Topotecan 5 Prednisolone 5 Fulvestrant 5 Dexamethasone 5 130-nm albumin-bound paclitaxel 5 toripalimab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07413939 2026-03-10

BREnnA

Hoffmann-La Roche

Phase 2/3 Not yet recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡